Immunogenicity of Monovalent Type 2 Oral Poliovirus Vaccine

计划入组 760 人 · 首次发布于 2015 年 12 月 31 日

Immunogenicity of Novel Oral Poliovirus Vaccine Type 2 (nOPV2), bOPV and IPV

计划入组 880 人 · 首次发布于 2023 年 11 月 2 日

Immunogenicity nOPV2 With and Without bOPV

计划入组 795 人 · 首次发布于 2020 年 10 月 8 日

Poliovirus type 2 antigen (formaldehyde inactivated)(Ipol, Kinrix, Pediarix, Pentacel, Quadracel, Vaxelis)

Poliovirus type 1 antigen (formaldehyde inactivated)(Ipol, Kinrix, Pediarix, Pentacel, Quadracel, Vaxelis)

Poliovirus type 3 antigen (formaldehyde inactivated)(Ipol, Kinrix, Pediarix, Pentacel, Quadracel, Vaxelis)

AIM VACCINE

China

Finlay Vaccine Institute

MEREO BIOPHARMA 2 LIMITED

United Kingdom

Biological E Receives WHO Phase II Pre-Qualification for Novel Oral Polio Vaccine Type 2

Novel Oral Polio Vaccines Demonstrate Safety and Efficacy in First-in-Human Phase 1 Trial

WHO TAG-CO-VAC Reviews COVID-19 Vaccine Effectiveness and Antigen Composition